Ovarian cancer treatment typically involves a combination of surgery and chemotherapy, with additional targeted therapies selected based on your tumor’s genetic profile. The specific plan depends on the cancer’s stage, how far it has spread, and whether your tumor carries certain mutations. When caught early (localized), the five-year survival rate is 91.7%, but 55% of cases are diagnosed after the cancer has already spread to distant sites, where survival drops to 31.8%. Understanding the full range of treatment options can help you have more informed conversations with your oncology team.
Surgery Is Usually the First Step
The primary goal of ovarian cancer surgery is to remove as much visible tumor as possible, a process called debulking or cytoreduction. This typically involves removing both ovaries, the fallopian tubes, the uterus, and any visible tumor deposits on nearby tissue. For the surgery to provide maximum survival benefit, the surgeon aims to leave no remaining tumor implants larger than 1 cm. When that threshold is met, it’s considered “optimal” debulking.
Not everyone is a candidate for surgery right away. If the cancer is very advanced or you aren’t healthy enough for a major operation, your oncologist may recommend starting with chemotherapy first (called neoadjuvant chemotherapy) to shrink the tumor. Surgery then happens after several rounds of chemo, at which point it’s called interval debulking surgery. This approach can make it easier for the surgeon to remove the remaining cancer completely.
If cancer returns after initial treatment, a second surgery may be considered. This tends to work best when there’s a single isolated recurrence, you’ve been disease-free for more than 12 months since finishing primary treatment, and the surgeon believes they can remove all or nearly all visible tumor.
Chemotherapy After Surgery
The standard first-line chemotherapy for ovarian cancer combines two drugs, a platinum-based agent and a taxane, given intravenously. Treatment is delivered in cycles that repeat every 21 days, and most patients receive six cycles total, spanning roughly four to five months. This same combination is used across all stages and also serves as neoadjuvant therapy when surgery is delayed.
Side effects vary but commonly include fatigue, nausea, nerve tingling or numbness in the hands and feet (peripheral neuropathy), hair loss, and lowered blood counts that increase infection risk. Many of these side effects are manageable with supportive medications, and your care team will monitor bloodwork before each cycle to make sure your body is recovering enough to continue.
Genetic Testing Shapes Your Treatment
One of the most important steps early in treatment is testing your tumor for BRCA1 and BRCA2 mutations, along with a broader assessment of a characteristic called homologous recombination deficiency (HRD). These results directly determine which maintenance therapies you’ll be eligible for after chemotherapy.
BRCA testing originally existed to estimate familial cancer risk, but it now plays a central role in treatment selection. Roughly 15 to 20% of ovarian cancers involve a BRCA mutation, and these tumors respond especially well to a class of drugs called PARP inhibitors. If your tumor has a BRCA mutation, your progression-free survival on maintenance therapy can more than double compared to observation alone. Testing can be done on the tumor tissue itself (somatic testing) or through a blood sample (germline testing), and guidelines recommend both.
PARP Inhibitors as Maintenance Therapy
PARP inhibitors work by blocking a DNA repair pathway that cancer cells rely on to survive. When a tumor already has faulty DNA repair from a BRCA mutation or HRD, adding a PARP inhibitor effectively cuts off the cancer’s last repair lifeline, causing the cells to die. These drugs are taken as daily pills and are used as maintenance therapy, meaning you start them after your tumor has responded to chemotherapy and continue them for a set period to delay or prevent recurrence.
Two PARP inhibitors are FDA-approved for first-line maintenance: olaparib (Lynparza) and niraparib (Zejula). Olaparib is approved for women whose tumors carry a harmful BRCA mutation and who had a complete or partial response to platinum-based chemotherapy. It can also be combined with bevacizumab for patients with specific genetic alterations. Niraparib is approved more broadly and showed benefit even in patients without BRCA mutations, though the effect was strongest in women with HRD tumors. In the PRIMA trial, women with HRD tumors who took niraparib had a median progression-free survival of 22 months compared to 10 months with placebo.
The results for BRCA-mutated cancers are particularly striking. In the SOLO-1 trial, olaparib maintenance pushed progression-free survival far beyond what chemotherapy alone could achieve. Current standard practice is to continue olaparib maintenance for two years and niraparib for three years, then stop. These drugs do have side effects, including fatigue, nausea, and low blood counts, which require regular monitoring.
Immunotherapy for Specific Cases
Immunotherapy has a more limited role in ovarian cancer compared to some other cancers, but it is an option in certain situations. Pembrolizumab (Keytruda) is approved in combination with chemotherapy, with or without bevacizumab, for patients with platinum-resistant ovarian cancer whose tumors express a protein called PD-L1. Eligibility requires a specific lab test confirming PD-L1 expression at a certain level, and the treatment is intended for patients who have already received one or two prior treatment regimens.
This means immunotherapy currently applies mainly to recurrent disease that no longer responds to platinum-based drugs, not as a first-line treatment. Your oncologist will order the PD-L1 test on your tumor tissue to determine whether you qualify.
Hormone Therapy for Recurrent Disease
Hormone therapy is sometimes used for ovarian cancer that has come back and is no longer responding to platinum-based chemotherapy. It works because many ovarian tumors have hormone receptors on their surface. Among the most common subtypes, about 81% of high-grade serous tumors, 88% of low-grade serous tumors, and 77% of endometrioid tumors test positive for estrogen receptors.
The medications used include tamoxifen (which blocks estrogen receptors), aromatase inhibitors like letrozole and anastrozole (which reduce estrogen production), and less commonly, progesterone-based drugs. Hormone therapy tends to produce modest tumor responses rather than dramatic shrinkage, but it comes with far fewer side effects than chemotherapy. This makes it a reasonable option for managing slow-growing recurrent disease, particularly low-grade serous ovarian cancer, which is often less sensitive to chemotherapy. Guidelines from both U.S. and European oncology organizations list hormone therapy as an option for platinum-resistant, recurrent disease.
Heated Chemotherapy During Surgery
Hyperthermic intraperitoneal chemotherapy, or HIPEC, is a specialized procedure where heated chemotherapy is circulated directly inside the abdominal cavity during surgery. The idea is that delivering high concentrations of the drug directly to the surfaces where ovarian cancer spreads, while heating it to 41 to 43 degrees Celsius, kills more cancer cells than standard intravenous chemotherapy while reducing side effects in the rest of the body. Cancer cells are more sensitive to heat than normal cells, and certain chemotherapy drugs become more potent at higher temperatures.
HIPEC is most commonly considered for patients with newly diagnosed stage III ovarian cancer who have had at least stable disease after neoadjuvant chemotherapy and are undergoing interval surgery where optimal or complete tumor removal can be achieved. It’s not available at every hospital and is typically offered at specialized cancer centers with experienced surgical teams.
Managing Symptoms Throughout Treatment
Supportive care runs alongside every phase of ovarian cancer treatment. Common issues include chemotherapy-related nausea, peripheral neuropathy, fatigue, and the buildup of fluid in the abdomen (ascites), which causes bloating, discomfort, and difficulty eating. Ascites can be drained with a needle procedure that provides quick relief, though the fluid often re-accumulates.
Addressing these symptoms aggressively isn’t just about comfort. Effective symptom management helps you stay strong enough to continue treatment on schedule, which directly affects outcomes. Palliative care specialists can be involved at any point during treatment, not just at end of life, and their involvement has been shown to improve quality of life while helping patients tolerate ongoing therapy. If you’re struggling with side effects, asking for a palliative care referral is a reasonable step at any stage of your treatment.
How Stage Affects Outlook
Survival rates for ovarian cancer vary dramatically by how far the disease has spread at diagnosis. Localized disease, confined to the ovary, carries a five-year relative survival of 91.7%. When cancer has spread to nearby lymph nodes or tissues (regional), survival is 70.7%. For distant-stage disease, which accounts for the majority of diagnoses, the five-year survival is 31.8%. These numbers reflect cases diagnosed between 2015 and 2021 and don’t yet capture the full impact of newer maintenance therapies like PARP inhibitors, which entered widespread use during that period.
Treatment advances, particularly in maintenance therapy and genetic-guided treatment selection, are shifting these numbers. Women with BRCA-mutated tumors who receive PARP inhibitor maintenance after first-line chemotherapy are seeing meaningfully longer periods without disease progression than was possible even a decade ago. The gap between a BRCA-positive and BRCA-negative prognosis has widened in a hopeful direction: having a BRCA mutation, once considered purely bad news, now means access to some of the most effective targeted treatments available.